Alaw Therapeutics Announces Two Major Pipeline Milestones Advancing Brain-Penetrant CDK Oncology Programs

Alaw Therapeutics, clinical-stage biotechnology company developing precision oncology therapeutics designed to control oncogenic proliferation, tumor survival, and therapeutic resistance, today announced two major pipeline milestones advancing its next-generation cyclin-dependent kinase (CDK) inhibitor portfolio.